Dr. Poeschel on 6 Versus 4 Cycles of R-CHOP in Frontline DLBCL

Viola Poeschel, MD
Published: Tuesday, Dec 04, 2018



Viola Poeschel, MD, department of hematology, oncology and rheumatology, Saarland University Medical School, Germany, discusses outcomes of patients with diffuse large B-cell lymphoma (DLBCL) who were treated with 4 cycles of R-CHOP during the 2018 ASH Annual Meeting.

At a median follow-up of 66 months, the 3-year progression-free survival (PFS) rate was 94% for patients who received 6 cycles of frontline R-CHOP  compared with 96% in those who received 4 cycles of frontline R-CHOP followed by 2 cycles of rituximab. The 3-year overall survival rates at a median follow-up of 67 months were 98% versus 99%, respectively. 

<<< 2018 ASH Annual Meeting


Viola Poeschel, MD, department of hematology, oncology and rheumatology, Saarland University Medical School, Germany, discusses outcomes of patients with diffuse large B-cell lymphoma (DLBCL) who were treated with 4 cycles of R-CHOP during the 2018 ASH Annual Meeting.

At a median follow-up of 66 months, the 3-year progression-free survival (PFS) rate was 94% for patients who received 6 cycles of frontline R-CHOP  compared with 96% in those who received 4 cycles of frontline R-CHOP followed by 2 cycles of rituximab. The 3-year overall survival rates at a median follow-up of 67 months were 98% versus 99%, respectively. 

<<< 2018 ASH Annual Meeting

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x